TW201716776A - 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法 - Google Patents

藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法 Download PDF

Info

Publication number
TW201716776A
TW201716776A TW105142150A TW105142150A TW201716776A TW 201716776 A TW201716776 A TW 201716776A TW 105142150 A TW105142150 A TW 105142150A TW 105142150 A TW105142150 A TW 105142150A TW 201716776 A TW201716776 A TW 201716776A
Authority
TW
Taiwan
Prior art keywords
vegf
tumor
antagonist
antibody
antigen
Prior art date
Application number
TW105142150A
Other languages
English (en)
Chinese (zh)
Inventor
張力
Original Assignee
再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 再生元醫藥公司 filed Critical 再生元醫藥公司
Publication of TW201716776A publication Critical patent/TW201716776A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW105142150A 2011-11-10 2012-11-09 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法 TW201716776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US201261613538P 2012-03-21 2012-03-21

Publications (1)

Publication Number Publication Date
TW201716776A true TW201716776A (zh) 2017-05-16

Family

ID=47179020

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105142150A TW201716776A (zh) 2011-11-10 2012-11-09 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法
TW106138384A TW201806620A (zh) 2011-11-10 2012-11-09 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法
TW101141702A TWI604852B (zh) 2011-11-10 2012-11-09 藉由拮抗ｉｌ－６受體抑制腫瘤生長之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW106138384A TW201806620A (zh) 2011-11-10 2012-11-09 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法
TW101141702A TWI604852B (zh) 2011-11-10 2012-11-09 藉由拮抗ｉｌ－６受體抑制腫瘤生長之方法

Country Status (20)

Country Link
US (3) US20130122003A1 (enExample)
EP (1) EP2776468B1 (enExample)
JP (3) JP6144689B2 (enExample)
KR (1) KR101718748B1 (enExample)
CN (1) CN103930443B (enExample)
AR (1) AR088671A1 (enExample)
AU (2) AU2012335596B2 (enExample)
BR (1) BR112014011211A2 (enExample)
CA (1) CA2853836C (enExample)
IL (2) IL231854A (enExample)
IN (1) IN2014CN02923A (enExample)
JO (1) JO3370B1 (enExample)
MX (1) MX357837B (enExample)
MY (1) MY163953A (enExample)
RU (1) RU2648150C2 (enExample)
SG (1) SG11201401286QA (enExample)
TW (3) TW201716776A (enExample)
UY (1) UY34444A (enExample)
WO (1) WO2013071016A2 (enExample)
ZA (1) ZA201402414B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20180169230A1 (en) * 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN112004577B (zh) 2018-03-14 2024-11-22 湖南思为康医药有限公司 用于降低毒性的免疫细胞修饰以及其在过继细胞疗法中的用途
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CA3127669A1 (en) * 2019-01-07 2020-07-16 Hunan Siweikang Therapeutics Co. Ltd Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN116897165A (zh) * 2021-02-27 2023-10-17 典晶生物医药科技(苏州)有限公司 靶向il-6受体和血管生成因子的抗体融合蛋白

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Also Published As

Publication number Publication date
US20130122003A1 (en) 2013-05-16
TW201806620A (zh) 2018-03-01
RU2014118739A (ru) 2015-12-20
AR088671A1 (es) 2014-06-25
JP2017095489A (ja) 2017-06-01
KR20140095481A (ko) 2014-08-01
AU2018203666A1 (en) 2018-06-14
IL231854A0 (en) 2014-05-28
CA2853836C (en) 2019-07-23
US20140322215A1 (en) 2014-10-30
CN103930443A (zh) 2014-07-16
BR112014011211A2 (pt) 2017-04-25
KR101718748B1 (ko) 2017-03-22
JP6144689B2 (ja) 2017-06-07
JO3370B1 (ar) 2019-03-13
SG11201401286QA (en) 2014-05-29
RU2648150C2 (ru) 2018-03-22
EP2776468B1 (en) 2018-01-24
US9409990B2 (en) 2016-08-09
ZA201402414B (en) 2015-03-25
WO2013071016A3 (en) 2013-07-25
CN103930443B (zh) 2017-08-04
IN2014CN02923A (enExample) 2015-07-03
AU2012335596A1 (en) 2014-05-22
JP6283754B2 (ja) 2018-02-21
WO2013071016A2 (en) 2013-05-16
CA2853836A1 (en) 2013-05-16
TW201332569A (zh) 2013-08-16
TWI604852B (zh) 2017-11-11
UY34444A (es) 2013-05-31
JP2014534237A (ja) 2014-12-18
MY163953A (en) 2017-11-15
IL248620A0 (en) 2016-12-29
AU2012335596B2 (en) 2018-05-17
MX2014004886A (es) 2014-07-09
MX357837B (es) 2018-07-26
EP2776468A2 (en) 2014-09-17
US20170022279A1 (en) 2017-01-26
JP2018083841A (ja) 2018-05-31
IL231854A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
TWI604852B (zh) 藉由拮抗ｉｌ－６受體抑制腫瘤生長之方法
US10400036B2 (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
CN104411722B (zh) 抗egfr抗体及其使用
CN102549015B (zh) 针对人血管生成素-2的高亲和力人抗体
HK1197681B (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1197681A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor